Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S1P receptor modulation and microglial activation in multiple sclerosis
2013-004626-28Phase 4Completed
- Sponsor
- Turku University Hospital
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fingolimod in multiple sclerosis (MS) (3 arms), sponsored by Turku University Hospital. Primary endpoint: Microglial activation. Started Nov 2013; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-004626-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004626-28.